1 / 7

Spinal Muscular Atrophy Market Size

Spinal muscular atrophy disease incidence of approximately 1 in 10,000 newborns and a prevalence of approximately 1 to 2 per 100,000 persons, globally. Spinal muscular atrophy is basically 4 types – Type 1, Type 2, Type 3 and Type 4. Most patients suffers with Spinal muscular atrophy type 1. According to Renub Research Global Spinal Muscular Atrophy (SMA) market is anticipated to grow at a CAGR of 14.29 percent in future. Renub Research report titled “Spinal Muscular Atrophy Market Global Forecast by Countries, Drugs & Companies” studies the global spinal muscular atrophy market.<br>Access full Research: <br>https://www.renub.com/spinal-muscular-atrophy-market-p.php

renubresearch
Download Presentation

Spinal Muscular Atrophy Market Size

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Spinal Muscular Atrophy Market

  2. Report Description and Highlights Analyst View: Spinal muscular atrophy disease incidence of approximately 1 in 10,000 newborns and a prevalence of approximately 1 to 2 per 100,000 persons, globally.  Spinal muscular atrophy is basically 4 types – Type 1, Type 2, Type 3 and Type 4. Most patients suffers with Spinal muscular atrophy type 1. According to Renub Research Spinal Muscular Atrophy Market is anticipated to grow at a CAGR of 14.29 percent in future. This double digit growth rate will happen due to expected launch of new drugs, better reimbursement options and decline in drugs prices.      Renub Research report titled “Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)” studies the global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.

  3. Spinal Muscular Atrophy Market New Drugs are expected to launch in recent years Spinal muscular atrophy is a disease that causes muscle weakness which mostly appears in newborn children. Spinal Muscular Atrophy (SMA) type 1 develop in less than 6 months of newborn children in which patients are not in position to sit in their lifetime and normally they die within 6 months.  In spinal muscular atrophy type 2, patients can sit but cannot walk. Type 2 is developed between 6-18 months of the new born children. Spinal muscular atrophy Type 3 patients can sit and walk and it developed when children age is less than 18 months. Spinal muscular atrophy Type 4 can develop during the adulthood.  Spinal Muscular Atrophy Market New Drugs are expected to launch in recent years At present only Biogen’sSpinraza is approved for the treatment of spinal muscular atrophy patients in the various parts of the globe such as United States, Europe, and Japan etc.  Other companies are also working for new drugs development and they hope to enter in the market place very soon as their drugs are in Phase III clinical trials.   Read more here: https://www.renub.com/spinal-muscular-atrophy-market-p.php

  4. Spinal Muscular Atrophy Patient Population Share Global – Current & Forecast for Spinal Muscular Atrophy Patient Population Share (Percent), 2017 – 2026 Source: Renub Research Analysis Note: These are dummy figures; actual data given in the report

  5. Spinal muscular atrophy market by country has been segmented into US, UK, France, Germany, Spain, Italy & Japan By Country - Market Segmentation Spinal muscular atrophy market by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is a leading market place due to increasing number of treated Patients, favorable reimbursement policies and increase in healthcare expenditure. By Total & Treated Patients - Population Segmentation Spinal muscular atrophy Total & Treated Patients by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is dominating in the treated SMA patients globally.  By Drugs - Market Segmentation The report by Renub Research studies the spinal muscular atrophy six drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) details with present and estimated global sales. Want more Information about this market? Request a free sample copy: https://www.renub.com/contactus.php

  6. Spinal Muscular Atrophy Treated Patients (Number) Global – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026 Source: Renub Research Analysis Note: These are dummy figures; actual data given in the report

  7. Countries, Drugs and Companies covered in this report Country Covered •    United States•    United Kingdom•    France •    Germany•    Italy •    Spain•    Japan Drugs Details Covered •    Spinraza•    AVXS-101•    CK2127107•    RG7916•    Olesoxime•    LMI070 Company Covered •    Biogen Inc.•    Roche AG•    Novartis AG•    Cytokinetics Inc • Browse Related Report : • Multiple Sclerosis Market • US Generic Drugs Market • Contact Us • Tel: +1-678-302-0700 (US), +91-120-421-9822 (INDIA) • Email: info@renub.com

More Related